Working… Menu

A Study of DSP-0337 in Patients With Advanced Solid Tumors to Determine the Safety and the Pharmacokinetic Profile

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT03416816
Recruitment Status : Terminated (Alternate development strategy)
First Posted : January 31, 2018
Last Update Posted : November 20, 2020
Syneos Health
Information provided by (Responsible Party):
Sumitomo Dainippon Pharma Oncology, Inc

Brief Summary:
This is a Phase 1, open label, multi-center study of orally administered DSP-0337 in adult subjects with advance solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.

Condition or disease Intervention/treatment Phase
Neoplasms Drug: DSP-0337 Phase 1

Detailed Description:
The study is comprised of two parts: an initial dose escalation phase utilizing a 3 + 3 design to determine maximum tolerated dose followed by a dose expansion cohort in approximately 30 additional subjects. Study participants will initially receive DSP-0337 orally for 28 days (one cycle of treatment). If clinical benefit is seen, treatment can continue until disease progression.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 23 participants
Allocation: N/A
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A First-in-Human Phase I Trial to Determine the Safety and the Pharmacokinetic Profile of DSP-0337 in Patients With Advanced Solid Tumors
Actual Study Start Date : May 15, 2018
Actual Primary Completion Date : June 15, 2020
Actual Study Completion Date : June 15, 2020

Arm Intervention/treatment
Experimental: DSP-0337
In Part 1 - Up to six dose levels will be investigated in dose-escalating cohorts to identify a maximum tolerated dose (MTD). An additional subset of patients will be treated to assess the effect of food intake on the PK of DSP-0337 administration at the MTD level. Once the recommended Phase 2 dose (RP2D) has been established, patients will be treated with the RP2D to explore preliminary antitumor activity and safety profile.
Drug: DSP-0337
DSP-0337 will be administered at the following doses in dose-escalation cohorts, maximum tolerated dose (MTD) for food effect, and recommended phase 2 dose (RP2D) for dose-expansion cohort. Dose 1: 200 mg once daily, Dose 2: 200 mg twice daily, Dose 3: 400 mg twice daily, Dose 4: 600 mg twice daily, Dose 5: 800 mg twice daily, Dose 6: 1000 mg twice daily.

Primary Outcome Measures :
  1. Maximum tolerated dose by assessing dose-limiting toxicities (DLTs) [ Time Frame: 4 weeks ]
    Dose escalating cohort

  2. Determination of the Recommended Phase 2 Dose (RP2D) by assessing dose-limiting toxicities (DLTs) [ Time Frame: 4 weeks ]
    Dose escalating cohort

Secondary Outcome Measures :
  1. Number of Patients with Adverse Events [ Time Frame: 12 months ]
    Tolerability will be evaluated based on the adverse events (AEs) recorded at each contact with the patient, physical examinations, and the results of laboratory tests. Toxicity will be graded according to the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03.

  2. Pharmacokinetics by assessing drug concentration in blood [ Time Frame: 4 weeks ]
    For food effect, dose escalating cohort

  3. Urine excretion of napabucasin after DSP-0337 administration [ Time Frame: 24 hours ]
    Twenty four-hour urine will be collected and excretion of napabucasin will be evaluated.

  4. Objective response rate (ORR) [ Time Frame: 6 months ]
    Defined as the proportion of patients with a documented complete response or partial response (CR + PR) based on RECIST 1.1.

  5. Time to progression (TTP) [ Time Frame: 6 months ]
    Defined as the time from first dose to the earlier date of assessment of progression by RECIST v1.1.

  6. Progression free survival (PFS) [ Time Frame: 12 months ]
    Defined as the time from first dose to the earlier date of assessment of progression or death by any cause in the absence of progression by RECIST v1.1.

Other Outcome Measures:
  1. Exploratory pharmacodynamic evaluation, including phosphorylated STAT3 (pSTAT3) expression level in patient-derived tumor tissue, as potential biomarkers [ Time Frame: 12 months ]

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria

  1. Histologically or cytologically confirmed diagnosis of advanced cancer in patients with solid tumors that are refractory to standard treatment, or for whom no effective therapy exists.
  2. Patients must have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
  3. Patients must be at least 18 years of age.
  4. Organ function must be adequate as follows:

    • Bone Marrow Reserve: absolute neutrophil count ≥ 1.5 x 10^9/L; platelet count ≥ 100 x 10^9/L; hemoglobin ≥ 9.0 g/dL. Must not have required blood transfusion within 1 week of baseline blood count assessment.
    • Hepatic: bilirubin < 1.5 times the upper limit of normal (ULN); alkaline phosphatase (AP), aspartate transaminase (AST), and alanine transaminase (ALT) < 3.0 x ULN (AP, AST, and ALT < 5 x ULN is acceptable if the liver has tumor involvement).
    • Renal: serum creatinine within normal limits; for patients with levels above the institutional normal value, the calculated corrected creatinine clearance must be ≥ 60 mL/min/1.73 m^2 using the Cockcroft-Gault formula corrected for the body surface area.
  5. Toxicities incurred as a result of previous anti cancer therapy (radiation therapy [RT], chemotherapy, or surgery) must be resolved to ≤ Grade 1 except for alopecia and anorexia.
  6. Patients must provide written informed consent.
  7. Female patients are eligible for the study if they meet the following criteria:

    • Are not pregnant or nursing;
    • Of non-childbearing potential defined as women who have had a hysterectomy, bilateral oophorectomy, medically documented ovarian failure, or are documented postmenopausal (follicle stimulating hormone > 40 mIU/mL); OR,

    Of childbearing potential defined as including women < 55 years of age, even those who have experienced 2 years of amenorrhea; all women should also meet both of the following criteria:

    • A negative serum or urine pregnancy test during Screening,
    • Sexually abstinent or correct and consistent use of one of the following methods of birth control in addition to a male partner using a condom from Screening to 3 months after the last dose of study drug:
    • hormone-containing contraceptive intrauterine device with a failure rate of < 1% per year,
    • cervical cap or diaphragm with a spermicidal agent,
    • tubal sterilization, or
    • vasectomy in male partner. Male patients must agree to sexual abstinence or to consistently and correctly use a condom in combination with one of the above methods of birth control from Screening to 3 months after the last dose of study drug.
  8. Life expectancy must be ≥ 3 months.

Exclusion Criteria

  1. Has received systemic anti-cancer therapy within the 3 weeks prior to starting the trial.
  2. Has received radiotherapy within the 28 days prior to first dose or within 12 weeks for patients with glioblastoma, with the exception of palliative radiotherapy to focal lesions for pain or other symptom control.
  3. Has received major surgery within the 4 weeks prior to starting the trial.
  4. Has significant inter-current illness including, but not limited to, ongoing or active infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with the study requirements.
  5. Clinically active known brain metastasis unless the brain metastases have been previously treated and are considered stable. Stable brain metastases are defined as no change on computed tomography (CT) scan or magnetic resonance imaging (MRI) for a minimum of 2 months and no change in steroid dose for a minimum of 4 weeks prior to starting the trial.
  6. Is pregnant or lactating.
  7. Had prior malignancy other than carcinoma in situ of the cervix or non-melanoma skin cancer, unless that prior malignancy was diagnosed and definitively treated at least 3 years previously with no subsequent evidence of recurrence. If the patient has a medical history of a previous tumor that is not included in this criteria and that the Investigator feels is irrelevant for the objectives of the study, it should be evaluated with the Sponsor or Medical Monitor.
  8. Has a corrected QT interval (QTc) > 470 ms or has an electrocardiogram (ECG) with a new abnormal finding that is clinically significant.
  9. Has a known clinically significant GI disorder(s) including, but not limited to, inflammatory bowel disease or a history of extensive gastric resection and/or small intestinal resection.
  10. Has inability to take oral medications and/or has clinical or radiological diagnosis of bowel obstruction.
  11. Had prior treatment with napabucasin (BBI-608).
  12. Is not able to avoid the concomitant use of proton pump inhibitors (PPIs) or histamine H2-receptors antagonists, which have long-lasting pH-elevating effects, during DSP-0337 dosing, or avoid the use of antacids until at least 2 hours after dosing.
  13. Has a known history of human immunodeficiency virus (HIV) infection, active hepatitis B, or untreated hepatitis C; patients who have completed a course of antiviral treatment for hepatitis C are eligible.
  14. Has inability to comply with the protocol or study procedures.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT03416816

Layout table for location information
United States, Indiana
Indiana University Health Melvin and Bren Simon Cancer Center
Indianapolis, Indiana, United States, 46202
United States, Michigan
Karmos Cancer Center
Detroit, Michigan, United States, 48201
United States, Texas
UT Heatlh San Antonio
San Antonio, Texas, United States, 78229
United States, Utah
Utah Cancer Specialist
West Jordan, Utah, United States, 84088
Sponsors and Collaborators
Sumitomo Dainippon Pharma Oncology, Inc
Syneos Health
Layout table for additonal information
Responsible Party: Sumitomo Dainippon Pharma Oncology, Inc Identifier: NCT03416816    
Other Study ID Numbers: BBI-DSP0337-101
First Posted: January 31, 2018    Key Record Dates
Last Update Posted: November 20, 2020
Last Verified: October 2020

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Sumitomo Dainippon Pharma Oncology, Inc: